Therapeutics MD (NYSEMKT: TXMD) has uniquely positioned itself to address a key issue in hormone therapy (NYSE:HT). The issue is this: in hormone therapy, monotherapies, or drugs that address a single hormonal issue, do not work well, because if a drug suppresses one problem hormone, the levels of another problem hormone go up. So, this creates a need for developing combination therapies in the HT market. However, the only FDA approved drugs available in the HT market are monotherapeutic bio-identicals. So, doctors are being forced to send women to compounding pharmacies, where non-FDA approved synthetic drugs are compounded to create over-the-counter hormone therapies. These therapies are extremely harmful, and can lead to severe side effects like cancer....
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|